Targeted Funding Opportunities

Competitive cancer-related funding opportunities to support Chao Family Comprehensive Cancer Center (CFCCC) members are available through both intramural and extramural sources. The extramural funding opportunities listed here are updated regularly, so check often.

 

If there are cancer-related opportunities that you would like us to review for posting, please contact CFCCC Administration (cfcccadmin@hs.uci.edu).

Healing Garden - Discover(small)

UCI Anti-Cancer Challenge Pilot Projects

The UCI Anti-Cancer Challenge is an annual ride, run, and walk that raises funds to support cancer-related pilot studies and early phase clinical trials that have been shown to improve quality of life and save lives. All of the funds raised are directed toward promising research led by UCI or CHOC scientists. For more information about the event, a list of previous and current awardees, and the RFP, please visit the link below.

Learn More

The CFCCC curates a list of cancer-relevant federal, non-federal, and limited submission opportunities. Search for extramural funding opportunities using the fields below.

Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01-Clinical Trial Optional)

PAR-22-131. Multiple deadlines. Earliest application due 10/5/2022.
This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that integrate imaging, biomarkers, digital pathomics, glycomics, metabolomics, other omic information and/or meta data obtained from platforms including but not limited to lower resolution diagnostic acquisitions and systemic biomarker results to high resolution single-cell analytics / imaging applied to the characterization of heterogeneous cell populations within tumor for improving current approaches for: (1) the early detection of organ confined premetastatic aggressive cancer, and, (2) identifying precancerous lesions associated with the development of a subsequent lethal phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions by improving detection sensitivity and specificity of integrated multiparametric platforms. For example, N-dimensional co-registered, cross-correlated imaging data integrated with multiplexed biomarker results and/or digital pathomics, glycomics, or metabolomic imaging using analytic strategies such as artificial intelligence or virtual reality visualization techniques. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to: (1) improve diagnostic performance by developing methodology for the early identification of potentially lethal cancer versus non-lethal disease, (2) minimize/better manage overdiagnosis and (3) reduce false positives and false negatives.